{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:53:42Z","timestamp":1761490422285,"version":"3.37.3"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Pharma AG, Grenzach-Wyhlen, Germany"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188602","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T13:43:14Z","timestamp":1511790194000},"page":"e0188602","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-8865","authenticated-orcid":true,"given":"Maria Rita","family":"Gaiser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Skorokhod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gransheier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Weide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Schif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"RL Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"GLOBOCAN Project (International Agency for Research on Cancer [IARC]\u2013specialized cancer agency of the World Health Organization [WHO]). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Population Fact Sheets: World. Accessed 15 August 2016; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx\" xlink:type=\"simple\">http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx<\/ext-link>."},{"key":"ref3","first-page":"386","article-title":"Dysplastic nevi. Markers for increased risk for melanoma","volume":"63","author":"DS Rigel","year":"1989","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.det.2008.12.002","article-title":"Melanoma epidemiology and public health","volume":"27","author":"M Berwick","year":"2009","journal-title":"Dermatol Clin"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"AS Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"JH Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"E Hodis","year":"2012","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"JA Jakob","year":"2012","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"JC Rubinstein","year":"2010","journal-title":"J Transl Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"GV Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"S Ugurel","year":"2007","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V<sup>600<\/sup>) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"S Moreau","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjd.12351","article-title":"Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma","volume":"169","author":"G Safaee Ardekani","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e86194","DOI":"10.1371\/journal.pone.0086194","article-title":"Survival according to BRAF-V600 tumor mutations\u2014an analysis of 437 patients with primary melanoma","volume":"9","author":"D Meckbach","year":"2014","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"A Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"Suppl. 5","key":"ref18","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"R Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"ref19","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>\u00ae<\/sup>): Melanoma. Version 1.2017. 2 May 2017."},{"key":"ref20","unstructured":"Hartmann A, Schirmacher P, Sterlacci W, Koch W, Schif B, Garbe C. BRAF mutation testing quality in malignant melanoma: Results from a German, observational, multicentre study. Presented at the XXXI International Congress of the IAP and 28th Congress of the ESP, 25\u201329 September 2016, Cologne, Germany. 2016: Abstract 60 (and associated poster presentation)."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"AM Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies","volume":"12","author":"G Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0560.2006.00646.x","article-title":"Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions","volume":"34","author":"JO Indsto","year":"2007","journal-title":"J Cutan Pathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaad.2012.03.022","article-title":"Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1","volume":"67","author":"A Skorokhod","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e59221","DOI":"10.1371\/journal.pone.0059221","article-title":"Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600)","volume":"8","author":"A Skorokhod","year":"2013","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/bjc.2013.143","article-title":"Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice","volume":"108","author":"L Heinzerling","year":"2013","journal-title":"Br J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T13:01:25Z","timestamp":1540299685000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188602"}},"subtitle":[],"editor":[{"given":"Roger","family":"Chammas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188602","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}